TTUHSC School of Pharmacy
HomeSOPFaculty & Staff Directory

Faculty & Staff Details

Profile for Molly Minze, PharmD

Molly Minze

Molly Minze, PharmD

  • Associate Professor
Office Phone: 325-696-0453
Mail Address: 1718 Pine St
Abilene TX 79601-3044


Dr. Minze is an Associate Professor of Pharmacy Practice at Texas Tech University Health Sciences Center School of Pharmacy. She is involved with didactic, laboratory teaching, facilitating case based learning, and Ambulatory Care clerkships. She maintains a practice site in Ambulatory Care at the Dyess Air Force Base in Abilene, Texas. Dr. Minze teaches in Endocrinology Pharmacotherapy, IPP 1 and 2, Drug Information, Case Studies III, and Grand Rounds.

Dr. Minze received her Bachelor of Science degree in Biomedical Science at Texas A&M University and Doctor of Pharmacy from the University of Houston College of Pharmacy in 2005. She then completed a pharmacy practice (PGY1) residency at the Veterans Affairs Medical Center Memphis, Tennessee and PGY2 ambulatory care residency at Coastal AHEC and New Hanover Regional Medical Center in Wilmington, North Carolina.

Selected Publications:

  • Minze MG, Chastain LM. Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide. Therapeutics and Clinical Risk Management 2016;2016(12):471-478.
  • Klein MS, Koffarnus R, Minze MG, Ochoa PS. Achieving cholesterol goals with low-cost 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-COA) reductase inhibitors in an indigent diabetic population. American Journal of Health Systems Pharmacists 2016;73(5 Supp 1):S63-8.
  • Minze MG, Y K, Hall RG. Low-molecular-weight heparin prophylaxis dosing: is weight an issue?. Journal of Pharmacy Technology 2015.
  • Minze MG, Black R, Bailey T, Diec S, Edwards KL. Sodium-glucose co-transporter 2 Inhibitors: Evidence and Place in Therapy. Expert Review of Endocrinology and Metabolism 2015;10(6):645-661.
  • Edwards KL, Minze MG, . Dulaglutide: An evidence-based review of its potential in the treatment of type 2 diabetes. Core Evidence 2015;10:11-21.